These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34165322)

  • 21. Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.
    Schultz NM; Penson DF; Wilson SD; Song Y; Yang H; Ramaswamy K; Lowentritt B
    J Manag Care Spec Pharm; 2019 Aug; 25(8):889-897. PubMed ID: 31172866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States.
    Seiter K; Latremouille-Viau D; Guerin A; Ndife B; Habucky K; Tang DH; Pivneva I; Gagnon-Sanschagrin P; Joseph GJ
    Adv Ther; 2018 Oct; 35(10):1671-1685. PubMed ID: 30155792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
    Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
    Int J MS Care; 2016; 18(6):314-323. PubMed ID: 27999526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Gan CL; Dudani S; Wells JC; Donskov F; Pal SK; Dizman N; Rathi N; Beuselinck B; Yan F; Lalani AA; Hansen A; Szabados B; de Velasco G; Tran B; Lee JL; Vaishampayan UN; Bjarnason GA; Subasri M; Choueiri TK; Heng DYC
    Cancer Med; 2021 Feb; 10(4):1212-1221. PubMed ID: 33463028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world treatment patterns of metastatic non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.
    Shenolikar R; Liu S; Shah A; Tse J; Cao Y; Near A
    Cancer Med; 2023 Jan; 12(1):159-169. PubMed ID: 35702932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib.
    MacLean E; Mardekian J; Cisar LA; Hoang CJ; Harnett J
    J Manag Care Spec Pharm; 2016 Aug; 22(8):979-90. PubMed ID: 27459661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
    Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
    Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost impact of disease progression to metastatic castration-sensitive prostate cancer.
    Trinh QD; Chaves LP; Feng Q; Zhu J; Sandin R; Abbott T
    J Manag Care Spec Pharm; 2022 May; 28(5):544-554. PubMed ID: 35471070
    [No Abstract]   [Full Text] [Related]  

  • 30. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
    Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
    [No Abstract]   [Full Text] [Related]  

  • 32. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
    Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
    J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma.
    Tawbi H; Bartley K; Seetasith A; Kent M; Lee J; Burton E; Haydu L; McKenna E
    J Manag Care Spec Pharm; 2022 Mar; 28(3):342-353. PubMed ID: 35199578
    [No Abstract]   [Full Text] [Related]  

  • 34. Economic burden of acute steroid-refractory graft-versus-host disease in commercially insured pediatric patients.
    Grabner M; Strati E; Sandman K; Forsythe A
    J Manag Care Spec Pharm; 2021 May; 27(5):607-614. PubMed ID: 33908282
    [No Abstract]   [Full Text] [Related]  

  • 35. All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States.
    Mostaghimi A; Gandhi K; Done N; Ray M; Gao W; Carley C; Wang T; Swallow E; Sikirica V
    J Manag Care Spec Pharm; 2022 Apr; 28(4):426-434. PubMed ID: 35332790
    [No Abstract]   [Full Text] [Related]  

  • 36. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
    Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
    [No Abstract]   [Full Text] [Related]  

  • 37. RENO Study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain.
    Badiola LB; Milagro NL; Lavín DC; Peraita SL; Ibarbia MA; Kareaga MM; Fernández Del Rivero TP; Otero DSP; López VA; Fernández CÁ; Emborujo AL; Arnaiz IG; Rodríguez RF; Sagastibeltza N; Duran I;
    Semin Oncol; 2024 Mar; ():. PubMed ID: 38604897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis.
    Yi E; Dai D; Piao OW; Zheng JZ; Park Y
    J Manag Care Spec Pharm; 2021 Jan; 27(1):27-36. PubMed ID: 33043820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The economic burden of HIV-associated wasting in the era of modern antiretroviral therapy.
    Siddiqui J; Samuel SK; Hayward B; Wirka KA; Deering KL; Harshaw Q; Phillips A; Harbour M
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1180-1189. PubMed ID: 35939048
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.